Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CEO Purchases $55,446.56 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CEO Anand Kiran Parikh purchased 2,806 shares of Sensei Biotherapeutics stock in a transaction on Monday, June 22nd. The shares were acquired at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Sensei Biotherapeutics Stock Up 2.2%

Shares of FTH stock traded up $0.54 during mid-day trading on Wednesday, hitting $24.54. 102,858 shares of the company’s stock were exchanged, compared to its average volume of 189,941. The stock has a market capitalization of $32.93 million, a price-to-earnings ratio of -0.17 and a beta of -0.25. Sensei Biotherapeutics, Inc. has a fifty-two week low of $6.32 and a fifty-two week high of $36.76.

Analysts Set New Price Targets

Several research firms have commented on FTH. HC Wainwright began coverage on Sensei Biotherapeutics in a report on Monday. They issued a “buy” rating and a $60.00 price target for the company. Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Finally, BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Sensei Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $60.00.

Key Stories Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: HC Wainwright maintained a bullish stance on Sensei Biotherapeutics and reiterated a $60 target, which may have supported investor sentiment despite the company’s expected losses.
• Neutral Sentiment: The firm updated multiple earnings estimates for 2026-2030, forecasting continued losses in the near and medium term, including EPS estimates of ($0.63) for Q2 2026, ($0.69) for Q3 2026, and ($0.75) for Q4 2026.
• Neutral Sentiment: HC Wainwright also projected losses for later years, including FY2027 EPS of ($3.72), FY2028 EPS of ($3.19), FY2029 EPS of ($3.16), and FY2030 EPS of ($3.07), reflecting a long path to profitability.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.